À propos de CARE™
Le Comité académique de CARE™ célèbrera sa 15e année en 2020 et entend poursuivre le débat en cours sur les biosimilaires et l’accès à l’innovation à l’aide d’un programme robuste en 2020 et au-delà.
Nous élaborons des initiatives de formation destinées à nos pairs, aux infirmières, aux pharmaciens, aux patients, au gouvernement ainsi qu’aux payeurs du secteur privé.
SAVOIR PLUS
Événements actuels
Publications [récentes]
CARE™ at ASH happened on December 6th, 2019. It is the largest gathering of hematologists outside of Canada. CARE™ has provided a summary report and the speaker slides presentations.
Voir la publication
Hematology
CARE™ at ASH 2019:
Presentations & Report
Rheumatology
CARE™ Perspectives:
More Innovation Needed in Rheumatology
Select members of the CARE™ Rheumatology Faculty used the 2019 ACR conference as an opportunity to meet and discuss the impact of, and continued support for access to innovation and biosimilar adoption, specifically from a Canadian context/perspective.
Voir la publication
The CARE™ ACG/UEGW 2019 Conference Report highlights key news in gastroenterology with a specific focus on inflammatory bowel disease (IBD), framed from a Canadian perspective.
Voir la publication
Gastroenterology
CARE™ Perspectives:
ACG/UEGW 2019
Genitourinary
CARE™ Perspectives:
ESMO 2019
2018 and 2019 have seen numerous data updates and news that could affect the management of prostate cancer (PC) in Canada. The following CARE™ Conference Report from ESMO 2019 focuses on prostate cancer updates.
Voir la publication
Publications actuels
The COVID-19 outbreak requires that select meetings be postponed as digital meeting formats are being considered. Education is always needed to make informed decisions. The various CARE™ faculty/staff continue to develop programming/outputs framed from a Canadian perspective.
CARE™ Perspectives from ASCO GUCS includes conference key news, updates to PC treatment algorithm, along with guidance and case study content
To access report click here: https://bit.ly/2JsjKtq
